Home › Targets › EGFR

EGFR (8 companies · 16 programs)

Companies with an active program directed at EGFR.

Vir Biotechnology, Inc. VIR

VIR-5525 — Non-Small Cell Lung Cancer Phase 1
VIR-5525 — Colorectal Cancer Phase 1
VIR-5525 — Head and Neck Squamous Cell Carcinoma Phase 1
VIR-5525 — Cutaneous Squamous Cell Carcinoma Phase 1
VIR-5525 Phase 1

Bicara Therapeutics Inc. BCAX

ficerafusp alfa — Head and Neck Squamous Cell Carcinoma Phase 2
ficerafusp alfa — Colorectal Cancer Phase 1
ficerafusp alfa — Cutaneous Squamous Cell Carcinoma Phase 1
ficerafusp alfa — Anal Squamous Cell Carcinoma Phase 1

Black Diamond Therapeutics, Inc. BDTX

silevertinib — Non-Small Cell Lung Cancer Phase 2
silevertinib — Glioblastoma Phase 2

Cullinan Therapeutics, Inc. CGEM

zipalertinib — Non-Small Cell Lung Cancer NDA Submitted

Erasca, Inc. ERAS

ERAS-12 Preclinical

Kairos Pharma, LTD. KAPA

CL-273 — Non-Small Cell Lung Cancer Preclinical

Oric Pharmaceuticals, Inc. ORIC

enozertinib — Non-Small Cell Lung Cancer Phase 1

Syndax Pharmaceuticals Inc SNDX

SNDX-4321 — Non-Small Cell Lung Cancer Preclinical